JP2002528393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002528393A5 JP2002528393A5 JP2000577627A JP2000577627A JP2002528393A5 JP 2002528393 A5 JP2002528393 A5 JP 2002528393A5 JP 2000577627 A JP2000577627 A JP 2000577627A JP 2000577627 A JP2000577627 A JP 2000577627A JP 2002528393 A5 JP2002528393 A5 JP 2002528393A5
- Authority
- JP
- Japan
- Prior art keywords
- tnf
- serum
- cells
- ccr5
- vlp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 32
- 210000002966 serum Anatomy 0.000 description 31
- 102000001327 Chemokine CCL5 Human genes 0.000 description 19
- 108010055166 Chemokine CCL5 Proteins 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 230000027455 binding Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 13
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 108010090804 Streptavidin Proteins 0.000 description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 7
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 7
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 102000045341 human CCL5 Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 6
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012286 ELISA Assay Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 102000001326 Chemokine CCL4 Human genes 0.000 description 4
- 108010055165 Chemokine CCL4 Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101100495162 Mus musculus Ccr5 gene Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 102000048160 human CCR5 Human genes 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108700031455 Bovine papillomavirus L2 Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101100438883 Homo sapiens CCR5 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000010729 leg swelling Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10513298P | 1998-10-21 | 1998-10-21 | |
| US60/105,132 | 1998-10-21 | ||
| PCT/US1999/024548 WO2000023955A1 (en) | 1998-10-21 | 1999-10-20 | Virus-like particles for the induction of autoantibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002528393A JP2002528393A (ja) | 2002-09-03 |
| JP2002528393A5 true JP2002528393A5 (enExample) | 2006-12-28 |
| JP4486257B2 JP4486257B2 (ja) | 2010-06-23 |
Family
ID=22304219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000577627A Expired - Lifetime JP4486257B2 (ja) | 1998-10-21 | 1999-10-20 | 自己抗体の誘導のためのウイルス様粒子 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US6719978B2 (enExample) |
| EP (1) | EP1123114B1 (enExample) |
| JP (1) | JP4486257B2 (enExample) |
| AT (1) | ATE314095T1 (enExample) |
| AU (1) | AU770802B2 (enExample) |
| CA (1) | CA2347411C (enExample) |
| DE (1) | DE69929232T2 (enExample) |
| ES (1) | ES2258869T3 (enExample) |
| WO (1) | WO2000023955A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| AU770802B2 (en) * | 1998-10-21 | 2004-03-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Virus-like particles for the induction of autoantibodies |
| ES2317711T3 (es) * | 1998-11-30 | 2009-04-16 | Cytos Biotechnology Ag | Presentacion molecular de alergenos, metodos de preparacion y uso. |
| US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| AU2007202761B2 (en) * | 2001-01-19 | 2010-01-21 | Kuros Biosciences Ag | Molecular antigen array |
| US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| FR2828404B1 (fr) * | 2001-08-10 | 2005-07-15 | Neovacs | Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal |
| ATE447967T1 (de) * | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| RU2350622C2 (ru) * | 2001-10-05 | 2009-03-27 | Цитос Байотекнолоджи Аг | Конъюгат ангиотензиновой пептидной составляющей с носителем, композиция вакцины, способ иммунизации животного и способ лечения или профилактики физического нарушения, ассоциированного с активируемой ренином ангиотензиновой системой |
| AU2002362696B2 (en) * | 2001-10-05 | 2008-05-29 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| BR0213117A (pt) | 2001-10-05 | 2004-09-21 | Cytos Biotechnology Ag | Conjugados peptìdeo angiotensina-veìculo e seus usos |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| KR20050044316A (ko) * | 2001-11-07 | 2005-05-12 | 사이토스 바이오테크놀로지 아게 | 호산구성 알레르기 질환 치료용의 ｉｌ-5, ｉｌ-13 또는에오탁신을 제시하는 항원 어레이 |
| JP4533626B2 (ja) * | 2001-11-07 | 2010-09-01 | サイトス バイオテクノロジー アーゲー | アレルギー性好酸球性疾患を治療するための抗原アレイ |
| PL369863A1 (en) * | 2001-11-07 | 2005-05-02 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| JP4658475B2 (ja) * | 2001-11-07 | 2011-03-23 | サイトス バイオテクノロジー アーゲー | 骨疾患治療用の抗原アレイ |
| US20030219459A1 (en) * | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
| US7285289B2 (en) | 2002-04-12 | 2007-10-23 | Nagy Jon O | Nanoparticle vaccines |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2004042001A2 (en) * | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
| US20040033585A1 (en) * | 2002-06-07 | 2004-02-19 | Mccormick Alison A. | Flexible vaccine assembly and vaccine delivery platform |
| RU2324704C2 (ru) | 2002-07-17 | 2008-05-20 | Цитос Байотекнолоджи Аг | Молекулярные массивы антигенов |
| EP2392345A3 (en) | 2002-07-18 | 2012-03-07 | Cytos Biotechnology AG | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| RU2450827C2 (ru) | 2002-07-19 | 2012-05-20 | Цитос Биотехнологи Аг | Композиции вакцин, содержащие наборы антигенов в виде амилоида бета 1-6 |
| WO2004032622A2 (en) * | 2002-09-03 | 2004-04-22 | Large Scale Biology Corporation | Production of peptides in plants as viral coat protein fusions |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| JP5022028B2 (ja) * | 2003-03-26 | 2012-09-12 | サイトス・バイオテクノロジー・アクチェンゲゼルシャフト | メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート |
| US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
| WO2005005614A2 (en) * | 2003-07-03 | 2005-01-20 | Pecos Labs, Inc. | Combined b-cell and t-cell epitopes on vlp for improved vaccines |
| WO2005068639A2 (en) * | 2004-01-20 | 2005-07-28 | Cytos Biotechnology Ag | Particle-induced ghrelin immune response |
| WO2005091753A2 (en) * | 2004-03-25 | 2005-10-06 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| RU2006146605A (ru) * | 2004-06-02 | 2008-07-20 | Цитос Биотехнологи Аг (Ch) | Медицинские применения конъюгатов-носителей tnf-пептидов из организма кроме человека |
| US20080019991A1 (en) * | 2004-06-02 | 2008-01-24 | Cytos Biotechnology Ag | Carrier Conjugates Of Tnf-Peptides |
| DE102004036913A1 (de) * | 2004-07-16 | 2006-02-09 | Responsif Gmbh | Verwendung von Pentameren zur Herstellung eines Medikaments |
| AU2005291231B2 (en) | 2004-10-05 | 2010-12-23 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
| CA2580919A1 (en) | 2004-10-25 | 2006-05-04 | Cytos Biotechnology Ag | Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof |
| GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| KR20070112225A (ko) * | 2005-03-18 | 2007-11-22 | 사이토스 바이오테크놀로지 아게 | 고양이 알레르겐 컨쥬게이트 및 그의 용도 |
| LT5414B (lt) * | 2005-04-13 | 2007-04-25 | Biotechnologijos Institutas | Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu |
| CN101193654A (zh) * | 2005-06-14 | 2008-06-04 | 赛托斯生物技术公司 | 抗原偶联物及其用途 |
| ES2310062B1 (es) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| CA2621466A1 (en) * | 2005-09-08 | 2007-04-05 | Kentucky Bioprocessing, Llc | Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications |
| KR20080047564A (ko) | 2005-09-28 | 2008-05-29 | 사이토스 바이오테크놀로지 아게 | 인터루킨-1 컨쥬게이트 및 그의 용도 |
| EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
| CA2671873C (en) | 2006-12-12 | 2018-10-09 | Brian Stephen Sproat | Oligonucleotides containing high concentrations of guanine monomers |
| EP2158211B1 (en) | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| US20090011996A1 (en) * | 2007-07-06 | 2009-01-08 | University Of Louisville Research Foundation, Inc. | Diagnosing and protecting horses against papillomavirus |
| EP2062592A1 (en) | 2007-11-20 | 2009-05-27 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | System for delivery into a XCR1 positive cell and uses thereof |
| EP2865389A1 (en) | 2008-12-09 | 2015-04-29 | Pfizer Vaccines LLC | IgE CH3 peptide vaccine |
| MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
| ES2670576T3 (es) | 2009-09-03 | 2018-05-31 | Pfizer Vaccines Llc | Vacuna de PCSK9 |
| US9301997B2 (en) | 2009-09-21 | 2016-04-05 | Peptinov Sas | Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides |
| CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| EP2755677B1 (en) * | 2011-09-15 | 2020-11-04 | Medigene AG | Anti-her2 vaccine based upon aav derived multimeric structures |
| EP2948469A4 (en) | 2013-01-23 | 2016-11-02 | Univ Leland Stanford Junior | STABILIZED HEPATITIS B CORE POLYPEPTIDE |
| WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
| WO2017071713A1 (en) | 2015-10-30 | 2017-05-04 | University Of Copenhagen | Virus like particle with efficient epitope display |
| CN112105733B (zh) | 2018-04-19 | 2024-10-29 | 查美特制药公司 | 合成rig-i样受体激动剂 |
| MX2022004825A (es) | 2019-10-23 | 2022-10-10 | Regeneron Pharma | Agonistas sintéticos del receptor similar a rig i. |
| WO2022140655A1 (en) * | 2020-12-23 | 2022-06-30 | The Trustees Of Columbia University In The City Of New York | Single-molecule electronic multiplex nanopore immunoassays for biomarker detection |
| WO2023235410A2 (en) * | 2022-06-01 | 2023-12-07 | The Regents Of The University Of California | Multivalent display of apoai peptide on nanoparticles against atherosclerosis |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| GB8903313D0 (en) | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
| US5714374A (en) | 1990-09-12 | 1998-02-03 | Rutgers University | Chimeric rhinoviruses |
| GB9114003D0 (en) * | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
| JPH0519914A (ja) * | 1991-07-17 | 1993-01-29 | Sharp Corp | 半導体装置の内部降圧回路 |
| KR940008286B1 (ko) * | 1991-08-19 | 1994-09-09 | 삼성전자 주식회사 | 내부전원발생회로 |
| CH684782A5 (de) | 1992-01-27 | 1994-12-30 | Rolf M Zinkernagel C O Inst Fu | Antigen zur Auslösung von CD8+ Zellimmunantworten. |
| KR950008453B1 (ko) * | 1992-03-31 | 1995-07-31 | 삼성전자주식회사 | 내부전원전압 발생회로 |
| US5618536A (en) | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US5723287A (en) | 1992-09-22 | 1998-03-03 | Medical Research Council | Recombinant viruses displaying a nonviral polypeptide on their external surface |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| US5721485A (en) * | 1996-01-04 | 1998-02-24 | Ibm Corporation | High performance on-chip voltage regulator designs |
| EP0927044A4 (en) | 1996-04-16 | 1999-09-08 | Immusol Inc | DEFINED TARGET VIRAL VECTORS |
| KR100224669B1 (ko) * | 1996-12-10 | 1999-10-15 | 윤종용 | 내부 전원 전압 발생기 회로 |
| US6171591B1 (en) * | 1997-12-08 | 2001-01-09 | Pentamer Pharmaceuticals, Inc. | Recombinant nodavirus compositions and methods |
| JPH11231954A (ja) * | 1998-02-16 | 1999-08-27 | Mitsubishi Electric Corp | 内部電源電圧発生回路 |
| DE19827457C1 (de) | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
| EP0994403B1 (en) * | 1998-10-15 | 2003-05-21 | Lucent Technologies Inc. | Current mirror |
| AU770802B2 (en) | 1998-10-21 | 2004-03-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Virus-like particles for the induction of autoantibodies |
| ES2317711T3 (es) | 1998-11-30 | 2009-04-16 | Cytos Biotechnology Ag | Presentacion molecular de alergenos, metodos de preparacion y uso. |
| US6373754B1 (en) * | 2000-07-17 | 2002-04-16 | Samsung Electronics Co., Ltd. | Semiconductor memory device having stable internal supply voltage driver |
| US20060210687A1 (en) * | 2002-11-06 | 2006-09-21 | Fiberstar, Inc. | Enhanced crackers, chips, wafers and unleavened using highly refined cellulose fiber ingredients |
-
1999
- 1999-10-20 AU AU12143/00A patent/AU770802B2/en not_active Expired
- 1999-10-20 AT AT99970772T patent/ATE314095T1/de not_active IP Right Cessation
- 1999-10-20 EP EP99970772A patent/EP1123114B1/en not_active Revoked
- 1999-10-20 JP JP2000577627A patent/JP4486257B2/ja not_active Expired - Lifetime
- 1999-10-20 DE DE69929232T patent/DE69929232T2/de not_active Expired - Lifetime
- 1999-10-20 ES ES99970772T patent/ES2258869T3/es not_active Expired - Lifetime
- 1999-10-20 CA CA2347411A patent/CA2347411C/en not_active Expired - Lifetime
- 1999-10-20 WO PCT/US1999/024548 patent/WO2000023955A1/en not_active Ceased
-
2001
- 2001-04-13 US US09/835,124 patent/US6719978B2/en not_active Expired - Lifetime
-
2002
- 2002-09-24 US US10/253,443 patent/US20030072753A1/en not_active Abandoned
-
2004
- 2004-06-14 US US10/867,119 patent/US7371572B2/en not_active Expired - Lifetime
-
2006
- 2006-05-01 US US11/415,611 patent/US7479280B2/en not_active Expired - Fee Related
-
2008
- 2008-03-18 US US12/050,892 patent/US7875450B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002528393A5 (enExample) | ||
| JP4486257B2 (ja) | 自己抗体の誘導のためのウイルス様粒子 | |
| ES2213754T3 (es) | Particulas quimericas de tipo papilomavirus. | |
| Wang et al. | Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease | |
| KR100263359B1 (ko) | IgE 관련 알레르기 반응의 치료용 IgE의 입실론 사슬의 정상부로 구성된 백신 | |
| JP2015527369A (ja) | アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法 | |
| KR20140039322A (ko) | 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법 | |
| US20240067706A1 (en) | Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof | |
| JP4205861B2 (ja) | 強化ワクチン | |
| WO2022071513A1 (ja) | ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン | |
| CN118126181B (zh) | 人和猴交叉种属抗ccr8膜蛋白抗体 | |
| CN118406159A (zh) | RSV pre-F截短体及其生产方法和应用 | |
| KR20020073149A (ko) | 핵산 백신접종 | |
| US20230414742A1 (en) | Novel vaccine for preventing and treating merkel cell carcinoma | |
| CN1994465B (zh) | Ccr5自体多肽疫苗及其制备方法 | |
| CN119708170B (zh) | RSV pre-F突变体及其制备方法和应用 | |
| WO2016192788A1 (en) | Methods and compositions for preventing and treating cat or dog dander allergy | |
| CN106883295B (zh) | 人内皮素a型受体免疫原性肽段及其载体疫苗 | |
| US20250228925A1 (en) | Methods and related aspects for increasing antigenic insertion sites on a recombinant immune complex platform | |
| EP1637166A2 (en) | Virus-like particles for the induction of autoantibodies | |
| CN118891272A (zh) | SARS-CoV-2刺突蛋白变体、其药物组合物及用途 | |
| JP2000504576A (ja) | エストロゲン応答エレメント結合タンパク質およびそれをコードするヌクレオチド | |
| WO2024173214A1 (en) | Sialokinin immunogen and methods for using same | |
| CN119119273A (zh) | 结合C5aR2膜蛋白的抗体及其制备方法 | |
| CN115569189A (zh) | 治疗hpv感染的疫苗组合 |